Match!

Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study

Published on May 1, 2019in Nature Medicine30.64
· DOI :10.1038/s41591-019-0380-z
Dominic G. Rothwell21
Estimated H-index: 21
,
Mahmood Ayub5
Estimated H-index: 5
+ 39 AuthorsMatthew Krebs14
Estimated H-index: 14
(University of Manchester)
Abstract
Sequencing of circulating tumor DNA from cancer patients is a cost-efficient approach with turnaround time compatible with clinical practice to inform treatment decision-making in a phase 1 trial setting
  • References (26)
  • Citations (4)
References26
Newest
#1Alexander Drilon (UTSW: University of Texas Southwestern Medical Center)H-Index: 24
#2Alex Drilon (UTSW: University of Texas Southwestern Medical Center)H-Index: 5
Last.Anna F. Farago (UTSW: University of Texas Southwestern Medical Center)H-Index: 19
view all 38 authors...
#1Viktor A. Adalsteinsson (MIT: Massachusetts Institute of Technology)H-Index: 11
#2Gavin Ha (Broad Institute)H-Index: 35
Last.Justin Rhoades (Broad Institute)H-Index: 5
view all 57 authors...
#1Tracy L. Stockley (U of T: University of Toronto)H-Index: 17
#2Amit M. Oza (U of T: University of Toronto)H-Index: 31
Last.Anthony M. Joshua (U of T: University of Toronto)H-Index: 31
view all 30 authors...
Cited By4
Newest
#1Jacob J. Adashek (USF: University of South Florida)
#2Patricia LoRusso (Yale Cancer Center)H-Index: 59
Last.Razelle Kurzrock (UCSD: University of California, San Diego)H-Index: 95
view all 4 authors...
#1Paul Hofman (French Institute of Health and Medical Research)H-Index: 60
#2Simon Heeke (French Institute of Health and Medical Research)H-Index: 4
Last.Klaus PantelH-Index: 94
view all 4 authors...
#1Nick Beije (Erasmus University Medical Center)H-Index: 5
#2John W. M. Martens (Erasmus University Medical Center)H-Index: 52
Last.Stefan Sleijfer (Erasmus University Medical Center)
view all 3 authors...
#1Hannah C. Wise (MSK: Memorial Sloan Kettering Cancer Center)
#2David B. Solit (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 79
View next paperMultidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer